Evidence map›Paper›PMID 41364185›Full record

ReviewDiscover oncology2025

The role of ADAM8 in intrahepatic cholangiocarcinoma.

Xilin Cui, Ziyi Wang, Chengkang Wang, Muxuan Jiang, Xiaoxuan Song, Yujuan Liu, Xinshan Deng, Xiaoling Wang, Yingshi Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xilin Cui *Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No.103 of Wenhua Road, Shenhe District, Shenyang city, 110016, Liaoning, People's Republic of China.
Ziyi Wang *Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No.103 of Wenhua Road, Shenhe District, Shenyang city, 110016, Liaoning, People's Republic of China.
Chengkang WangDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, No.103 of Wenhua Road, Shenhe District, Shenyang city, 110016, Liaoning, People's Republic of China.
Muxuan JiangGeneral Hospital of Northern Theater Command, China Medical University, No. 77, Puhe Road, Shenbei New District, Shenyang city, 110122, Liaoning, People's Republic of China.
Xiaoxuan SongDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, No.103 of Wenhua Road, Shenhe District, Shenyang city, 110016, Liaoning, People's Republic of China.
Yujuan LiuDepartment of Pharmacy, Lintong Rehabilitation and Sanatorium Center of the Joint Logistic Support Force, 710699, Xi'an city, People's Republic of China.
Xinshan DengHunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha City, 410219, Hunan Province, People's Republic of China.
Xiaoling WangDepartment of Pharmacy, Lintong Rehabilitation and Sanatorium Center of the Joint Logistic Support Force, 710699, Xi'an city, People's Republic of China. wangxiaolingk@163.com.
Yingshi ZhangDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, No.103 of Wenhua Road, Shenhe District, Shenyang city, 110016, Liaoning, People's Republic of China. zhangyingshi@syphu.edu.cn.

Funding

Natural Science Foundation of Liaoning Province 2025-MSLH-653Scientific Research Fund of Liaoning Provincial Education Department LJ212510163014
6 · The paper itself

Abstract

Currently, there are no approved first-line targeted inhibitors for ICC. ADAM8 is one of the most frequently over-expressed proteins in human intrahepatic cholangiocarcinoma (ICC). This review examines the potential of ADAM8 as a direct therapeutic target for ICC, emphasizing its downstream impact on Notch and Integrin signaling pathways. Collectively, these findings suggest ADAM8 may represent a novel strategy for ICC management. We have consolidated pre-clinical research on ADAM8 inhibitors, which demonstrate inhibitory effects on epithelial mesenchymal transition (EMT) and tumor angiogenesis by cleaving substrates such as CHL1 and CD23 to form their active fragments. And its substrate form may be monomers, dimers, or even polymers. This review provides a critical discussion of the therapeutic potential of ADAM8 inhibitors in ICC. However, further challenges remain, including enhancing inhibitor specificity, conducting long-term studies to thoroughly evaluate the benefits and risks associated with targeting ADAM8.

Indexed as

ADAM8Epithelial mesenchymal transitionIntegrin signaling pathwayIntrahepatic cholangiocarcinomaNotch signaling pathwayTumor angiogenesis

Identifiers

PMID41364185
PMCPMC12799872

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.